SEARCH

SEARCH BY CITATION

References

  • 1
    Reifenberger G, Kros J, Burger P, Louis D, Collins V. Oligodendroglial tumors and mixed gliomas. In: KleihuesP, CaveneeWK, eds. World Health Organization classification of tumours. Tumors of the nervous system: pathology and genetics. Lyon: IARC Press, 2000, 5570.
  • 2
    Roerig P, Nessling M, Radlwimmer B, Joos S, Wrobel G, Schwaenen C, Reifenberger G, Lichter P. Molecular classification of human gliomas using matrix-based comparative genomic hybridization. Int J Cancer 2005; 117: 95103.
  • 3
    Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003; 62: 11126.
  • 4
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 14739.
  • 5
    Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 83945.
  • 6
    Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 63645.
  • 7
    Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004; 14: 12130.
  • 8
    Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, Louis DN. Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res 2002; 62: 41008.
  • 9
    Wrobel G, Schlingemann J, Hummerich L, Kramer H, Lichter P, Hahn M. Optimization of high-density cDNA-microarray protocols by ‘design of experiments’. Nucleic Acids Res 2003; 31: e67.
  • 10
    Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004; 64: 310311.
  • 11
    Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 511621.
  • 12
    Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 656772.
  • 13
    Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 21525; discussion 226–9.
  • 14
    van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, Reifenberger G, Hanash SM. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003; 163: 103343.
  • 15
    Sambrook J, Russell DW. Molecular cloning: a laboratory manual, 3rd ed, 3 vols. Plainview, NY: Cold Spring Harbor Laboratory, 2001.
  • 16
    Boström J, Mühlbauer A, Reifenberger G. Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas. Acta Neuropathol (Berl) 1997; 94: 47985.
  • 17
    Baugh LR, Hill AA, Brown EL, Hunter CP. Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res 2001; 29: E29.
  • 18
    Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18 ( Suppl 1): S96S104.
  • 19
    Hosack DA, Dennis G,Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003; 4: R70.
  • 20
    Tews B, Wilhelm J, Summerer D, Strerath M, Marx A, Friedhoff P, Pingoud A, Hahn M. Application of the C4′-alkylated deoxyribose primer system (CAPS) in allele-specific real-time PCR for increased selectivity in discrimination of single nucleotide sequence variants. Biol Chem 2003; 384: 153341.
  • 21
    Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
  • 22
    Alaminos M, Davalos V, Ropero S, Setien F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, Esteller M. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 2005; 65: 256571.
  • 23
    Husemann K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenberger G. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999; 58: 104150.
  • 24
    Pohl U, Cairncross JG, Louis DN. Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 1999; 9: 63943.
  • 25
    Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005; 11: 111928.
  • 26
    Wolf RM, Draghi N, Liang X, Dai C, Uhrbom L, Eklof C, Westermark B, Holland EC, Resh MD. p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev 2003; 17: 47687.
  • 27
    Wang B, Li N, Sui L, Wu Y, Wang X, Wang Q, Xia D, Wan T, Cao X. HuBMSC-MCP, a novel member of mitochondrial carrier superfamily, enhances dendritic cell endocytosis. Biochem Biophys Res Commun 2004; 314: 292300.
  • 28
    Walker JE, Runswick MJ. The mitochondrial transport protein superfamily. J Bioenerg Biomembr 1993; 25: 43546.
  • 29
    Xu X, Shi YC, Gao W, Mao G, Zhao G, Agrawal S, Chisolm GM, Sui D, Cui MZ. The novel presenilin-1-associated protein is a proapoptotic mitochondrial protein. J Biol Chem 2002; 277: 4891322.
  • 30
    Kumar KU, Srivastava SP, Kaufman RJ. Double-stranded RNA-activated protein kinase (PKR) is negatively regulated by 60S ribosomal subunit protein L18. Mol Cell Biol 1999; 19: 111625.
  • 31
    Castets F, Rakitina T, Gaillard S, Moqrich A, Mattei MG, Monneron A. Zinedin, SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain. J Biol Chem 2000; 275: 199707.
  • 32
    Feng HC, Tsao SW, Ngan HY, Xue WC, Chiu PM, Cheung AN. Differential expression of insulin-like growth factor binding protein 1 and ferritin light polypeptide in gestational trophoblastic neoplasia: combined cDNA suppression subtractive hybridization and microarray study. Cancer 2005; 104: 240916.
  • 33
    Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part II: the C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol Rev 2004; 56: 291330.
  • 34
    Gachon F, Fonjallaz P, Damiola F, Gos P, Kodama T, Zakany J, Duboule D, Petit B, Tafti M, Schibler U. The loss of circadian PAR bZip transcription factors results in epilepsy. Genes Dev 2004; 18: 1397412.
  • 35
    Katoh M. Identification and characterization of FLJ10737 and CAMTA1 genes on the commonly deleted region of neuroblastoma at human chromosome 1p36.31-p36.23. Int J Oncol 2003; 23: 121924.
  • 36
    Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest 2004; 113: 53950.
  • 37
    Winter-Vann AM, Baron RA, Wong W, dela Cruz J, York JD, Gooden DM, Bergo MO, Young SG, Toone EJ, Casey PJ. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci USA 2005; 102: 433641.
  • 38
    Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23: 422531.
  • 39
    Hartmann C, Numann A, Mueller W, Holtkamp N, Simon M, von Deimling A. Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. Int J Cancer 2004; 108: 83944.
  • 40
    von Deimling A, Bender B, Jahnke R, Waha A, Kraus J, Albrecht S, Wellenreuther R, Fassbender F, Nagel J, Menon AG. Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. Cancer Res 1994; 54: 1397401.
  • 41
    Underwood KW, Song C, Kriz RW, Chang XJ, Knopf JL, Lin LL. A novel calcium-independent phospholipase A2, cPLA2-γ, that is prenylated and contains homology to cPLA2. J Biol Chem 1998; 273: 2192632.
  • 42
    Asai K, Hirabayashi T, Houjou T, Uozumi N, Taguchi R, Shimizu T. Human group IVC phospholipase A2 (cPLA2γ). Roles in the membrane remodeling and activation induced by oxidative stress. J Biol Chem 2003; 278: 880914.
  • 43
    Kokoglu E, Tuter Y, Yazici Z, Sandikci KS, Sonmez H, Ulakoglu EZ, Ozyurt E. Profiles of the fatty acids in the plasma membrane of human brain tumors. Cancer Biochem Biophys 1998; 16: 30112.
  • 44
    Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, Libner R, Davi G, Procopio A. 5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15: 232636.
  • 45
    Capodici C, Pillinger MH, Han G, Philips MR, Weissmann G. Integrin-dependent homotypic adhesion of neutrophils. Arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase-dependent pathway. J Clin Invest 1998; 102: 16575.